OC-0086: A sarcoma hypoxia signature (nanoString® assay) validates in the phase III VorteX radiotherapy trial

MLA

Lingjian Yang, et al. “OC-0086: A Sarcoma Hypoxia Signature (NanoString® Assay) Validates in the Phase III VorteX Radiotherapy Trial.” Radiotherapy and Oncology, vol. 152, Nov. 2020, pp. S39–40. EBSCOhost, https://doi.org/10.1016/s0167-8140(21)00112-2.

APA

Lingjian Yang, Patrick Shenjere, James P Wylie, Becky A.S. Bibby, Joely J Irlam, Helen R Valentine, Laura-Jane Forker, Michael G Leahy, Ananya Choudhury, Catharine M L West, Lucinda Billingham, Piers Gaunt, & Martin Robinson. (2020). OC-0086: A sarcoma hypoxia signature (nanoString® assay) validates in the phase III VorteX radiotherapy trial. Radiotherapy and Oncology, 152, S39–S40. https://doi.org/10.1016/s0167-8140(21)00112-2

Chicago

Lingjian Yang, Patrick Shenjere, James P Wylie, Becky A.S. Bibby, Joely J Irlam, Helen R Valentine, Laura-Jane Forker, et al. 2020. “OC-0086: A Sarcoma Hypoxia Signature (NanoString® Assay) Validates in the Phase III VorteX Radiotherapy Trial.” Radiotherapy and Oncology 152 (November): S39–40. doi:10.1016/s0167-8140(21)00112-2.